Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 9 |
List of Tables | 9 | 1 |
List of Figures | 10 | 1 |
Introduction | 11 | 1 |
Global Markets Direct Report Coverage | 11 | 1 |
Hemophilia A Overview | 12 | 1 |
Therapeutics Development | 13 | 2 |
Pipeline Products for Hemophilia A Overview | 13 | 1 |
Pipeline Products for Hemophilia A Comparative Analysis | 14 | 1 |
Hemophilia A Therapeutics under Development by Companies | 15 | 2 |
Hemophilia A Therapeutics under Investigation by Universities/Institutes | 17 | 1 |
Hemophilia A Pipeline Products Glance | 18 | 4 |
Late Stage Products | 18 | 1 |
Clinical Stage Products | 19 | 1 |
Early Stage Products | 20 | 1 |
Unknown Stage Products | 21 | 1 |
Hemophilia A Products under Development by Companies | 22 | 3 |
Hemophilia A Products under Investigation by Universities/Institutes | 25 | 1 |
Hemophilia A Companies Involved in Therapeutics Development | 26 | 30 |
Alnylam Pharmaceuticals Inc | 26 | 1 |
Amarna Therapeutics BV | 27 | 1 |
Apitope International NV | 28 | 1 |
Bayer AG | 29 | 1 |
Biogen Inc | 30 | 1 |
BioMarin Pharmaceutical Inc | 31 | 1 |
Catalyst Biosciences Inc | 32 | 1 |
Chugai Pharmaceutical Co Ltd | 33 | 1 |
CSL Ltd | 34 | 1 |
DBV Technologies SA | 35 | 1 |
Dimension Therapeutics Inc | 36 | 1 |
Emergent BioSolutions Inc | 37 | 1 |
EpiVax Inc | 38 | 1 |
Expression Therapeutics LLC | 39 | 1 |
Green Cross Corp | 40 | 1 |
Idogen AB | 41 | 1 |
Lentigen Technology Inc | 42 | 1 |
mAbxience SA | 43 | 1 |
Novo Nordisk A/S | 44 | 1 |
Octapharma AG | 45 | 1 |
OPKO Biologics Ltd | 46 | 1 |
Pfizer Inc | 47 | 1 |
Pharming Group NV | 48 | 1 |
rEVO Biologics Inc | 49 | 1 |
Sangamo BioSciences Inc | 50 | 1 |
Shire Plc | 51 | 1 |
SK Chemicals Co Ltd | 52 | 1 |
Spark Therapeutics Inc | 53 | 1 |
UniQure NV | 54 | 1 |
XL-protein GmbH | 55 | 1 |
Hemophilia A Therapeutics Assessment | 56 | 9 |
Assessment by Monotherapy Products | 56 | 1 |
Assessment by Target | 57 | 2 |
Assessment by Mechanism of Action | 59 | 2 |
Assessment by Route of Administration | 61 | 2 |
Assessment by Molecule Type | 63 | 2 |
Drug Profiles | 65 | 76 |
antihemophilic factor Drug Profile | 65 | 4 |
antihemophilic factor (human) Drug Profile | 69 | 4 |
antihemophilic factor (recombinant) Drug Profile | 73 | 1 |
antihemophilic factor (recombinant) Drug Profile | 74 | 1 |
antihemophilic factor (recombinant) Drug Profile | 75 | 1 |
antihemophilic factor (recombinant) Drug Profile | 76 | 1 |
antihemophilic factor (recombinant) Drug Profile | 77 | 1 |
antihemophilic factor (recombinant) Drug Profile | 78 | 1 |
antihemophilic factor (recombinant) biosimilar Drug Profile | 79 | 1 |
antihemophilic factor (recombinant) biosimilar Drug Profile | 80 | 1 |
antihemophilic factor (recombinant), pegylated Drug Profile | 81 | 2 |
antihemophilic factor (recombinant), single chain Drug Profile | 83 | 3 |
ATXF-8117 Drug Profile | 86 | 1 |
BAX-888 Drug Profile | 87 | 1 |
BAY-1093884 Drug Profile | 88 | 1 |
BMN-270 Drug Profile | 89 | 2 |
Cell Therapy to Target Coagulation Factor VIII for Hemophilia A Drug Profile | 91 | 1 |
coagulation factor VIIa (recombinant) Drug Profile | 92 | 2 |
coagulation factor VIII (human) Drug Profile | 94 | 1 |
concizumab Drug Profile | 95 | 1 |
CSL-689 Drug Profile | 96 | 2 |
damoctocog alfa pegol Drug Profile | 98 | 2 |
Deimmunized FVIII Drug Profile | 100 | 1 |
DTX-201 Drug Profile | 101 | 1 |
emicizumab Drug Profile | 102 | 3 |
ET-3 Drug Profile | 105 | 1 |
fitusiran Drug Profile | 106 | 6 |
Gene Therapy for Hematological Disorders Drug Profile | 112 | 1 |
Gene Therapy for Hemophilia A Drug Profile | 113 | 1 |
Gene Therapy to Activate Factor VIII for Hemophilia A Drug Profile | 114 | 1 |
IN-3012 Drug Profile | 115 | 1 |
Kovaltry Drug Profile | 116 | 2 |
LG-889 Drug Profile | 118 | 1 |
LR-769 Drug Profile | 119 | 2 |
marzeptacog alfa Drug Profile | 121 | 2 |
MG-1113A Drug Profile | 123 | 1 |
MOD-5014 Drug Profile | 124 | 3 |
PBB-8-IN Drug Profile | 127 | 1 |
PF-06741086 Drug Profile | 128 | 1 |
Recombinant Factor VIII Replacement for Hemophilia A Drug Profile | 129 | 2 |
Recombinant Factor VIII Replacement for Hemophilia A Drug Profile | 131 | 1 |
Recombinant Protein for Hemophilia A Drug Profile | 132 | 1 |
Recombinant Proteins for Hemophilia A Drug Profile | 133 | 1 |
SB-525 Drug Profile | 134 | 1 |
SB-FVIII Drug Profile | 135 | 2 |
SHP-656 Drug Profile | 137 | 2 |
SPK-8011 Drug Profile | 139 | 1 |
SVF-VIIa Drug Profile | 140 | 1 |
Hemophilia A Dormant Projects | 141 | 2 |
Hemophilia A Discontinued Products | 143 | 1 |
Hemophilia A Product Development Milestones | 144 | 14 |
Featured News &Press Releases | 144 | 1 |
Nov 14, 2016: AFSTYLA (rFVIII-SC) - CHMP recommendation | 144 | 1 |
Nov 03, 2016: Genentech to present data on Emicizumab at American Society of Hematology 2016 Annual Meeting | 144 | 1 |
Sep 12, 2016: Idogen reports important breakthrough - positive results from proof-of-concept study in human cells | 145 | 1 |
Aug 26, 2016: Chugai receives Orphan Drug Designation for Emicizumab - Preventing and Reducing the Frequency of Bleeding Episodes in Congenital FVlll Deficiency Patients with Inhibitors | 145 | 1 |
Aug 01, 2016: Shire Announces FDA Approval of adynovate with BAXJECT III Reconstitution System | 146 | 1 |
Jul 27, 2016: CSL Behring Presents Pivotal Efficacy Data for AFSTYLA In Adolescents and Children with Hemophilia A at the World Federation of Hemophilia 2016 World Congress | 146 | 2 |
Jul 27, 2016: Chugai Emicizumab Showed Continued Benefits in Patients with Hemophilia A | 148 | 1 |
Jul 26, 2016: ADYNOVATE Phase 3 Efficacy and Safety Data in Children to be Showcased During International Congress of the World Federation of Hemophilia | 149 | 1 |
Jul 26, 2016: Sangamo BioSciences Announces New Gene Therapy Clinical Development Program for Treatment Of Hemophilia A | 150 | 1 |
Jul 25, 2016: Alnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, a Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia and Rare Bleeding Disorders | 151 | 3 |
Jul 25, 2016: Alnylam to Report New Clinical Results with Fitusiran at the World Federation of Hemophilia 2016 World Congress | 154 | 1 |
Jul 19, 2016: Shire reinforces commitment in Hematology with robust data presented at international congress of the World Federation of Hemophilia | 154 | 1 |
Jul 19, 2016: CSL Behring to Present New Data for AFSTYLA at the World Federation of Hemophilia 2016 World Congress | 155 | 1 |
Jul 18, 2016: Biogen and Sobi to Showcase Data on FVIIIFc-VWF-XTEN at World Federation of Hemophilia 2016 World Congress | 156 | 1 |
Jun 20, 2016: AFSTYLA - CSL Behring Novel Recombinant Factor VIII Single Chain Therapy for Hemophilia A - Now Available in the U.S. | 156 | 2 |
Appendix | 158 | 2 |
Methodology | 158 | 1 |
Coverage | 158 | 1 |
Secondary Research | 158 | 1 |
Primary Research | 158 | 1 |
Expert Panel Validation | 158 | 1 |
Contact Us | 158 | 1 |
Disclaimer | 159 | 1 |